1. Home
  2. CSTL vs AFYA Comparison

CSTL vs AFYA Comparison

Compare CSTL & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$32.44

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo Afya Limited

AFYA

Afya Limited

N/A

Current Price

$15.01

Market Cap

1.4B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
CSTL
AFYA
Founded
2007
1999
Country
United States
Brazil
Employees
N/A
N/A
Industry
Medical Specialities
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
CSTL
AFYA
Price
$32.44
$15.01
Analyst Decision
Strong Buy
Hold
Analyst Count
6
4
Target Price
$46.67
$17.25
AVG Volume (30 Days)
407.5K
134.7K
Earning Date
02-26-2026
03-12-2026
Dividend Yield
N/A
1.55%
EPS Growth
N/A
25.39
EPS
N/A
1.50
Revenue
$343,530,000.00
$681,742,784.00
Revenue This Year
$2.88
$14.73
Revenue Next Year
N/A
$7.73
P/E Ratio
N/A
$10.00
Revenue Growth
10.15
14.07
52 Week Low
$14.59
$13.12
52 Week High
$44.28
$19.90

Technical Indicators

Market Signals
Indicator
CSTL
AFYA
Relative Strength Index (RSI) 24.66 54.76
Support Level $38.20 $13.34
Resistance Level $40.88 $15.46
Average True Range (ATR) 1.98 0.43
MACD -1.10 0.05
Stochastic Oscillator 3.79 80.66

Price Performance

Historical Comparison
CSTL
AFYA

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

Share on Social Networks: